These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37415001)

  • 1. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
    Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
    Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
    Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
    Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U; Jianmongkol S; Prueksaritanont T
    Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
    Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
    Gouin-Thibault I; Delavenne X; Blanchard A; Siguret V; Salem JE; Narjoz C; Gaussem P; Beaune P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA
    J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
    Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA; Profit L; Back DJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
    Huwyler J; Wright MB; Gutmann H; Drewe J
    Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M; Nakajima M; Yamazaki H; Yokoi T
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.
    Huang J; Si L; Jiang L; Fan Z; Qiu J; Li G
    Int J Pharm; 2008 May; 356(1-2):351-3. PubMed ID: 18242899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
    Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.